

NCIC CLINICAL TRIALS GROUP

GENITOURINARY**AGENDA**

DISEASE SITE COMMITTEE MEETING

Delta Chelsea Hotel, Toronto, ON

Saturday, May 2, 2009

9:00 a.m. – 3:30 p.m.

Room: Rossetti

Chair: Fred Saad

-
- 9:00 WELCOME, APPROVAL OF FALL MEETING MINUTES**
Chairman's Report Fred Saad
- 9:10 NCIC CTG/INTERGROUP PHASE III TRIALS: OPEN**
PR.11 L. Klotz
PR.12 M. McKenzie/K. Chi
PR.13 (RADICALS)/MRC PR.10 C. Catton/F. Saad
- 9:40 NCIC CTG/INTERGROUP PHASE III TRIALS: CLOSED**
BL 8/EORTC 30994 L. Wood/
BL.11 L. Lacombe
PR.3 P. Warde
PR.7/PR.7 Bone Sub Study J. Crook/L. Klotz
PR.8/SWOG 9346 B. Donnelly
PRP.1/PRP.1B N. Fleshner
- NCIC CTG/INTERGROUP PHASE III TRIALS: PENDING ACTIVATION**
None
- 10:10 CTSU TRIALS ACTIVATED BY NCIC CTG: OPEN**
- | | | |
|-------------------|--|-------------------|
| PRC.2/CALGB 90202 | HT with or without zoledronic acid
in hormone naïve met CaP | F. Saad |
| PRC.3/CALGB 90203 | Neoadjuvant Taxotere plus AS
prior to RP v.s. RP only | M.Gleave |
| REC.2/ECOG E2805 | Sunitinib/placebo vs. Sorafenib/placebo vs.
placebo in resected RCC | M. Jewett/L. Wood |
- CTSU TRIALS: PENDING ENDORSEMENT/ACTIVATION**
None
- 10:30 BREAK**
- 11:00 NCIC CTG IND TRIALS**
IND.165 Randomized Phase II (OGX-011 +/- docetaxel HRPC) (closed) K. Chi

IND.19X: A Phase II Study of SB 939 in Patients with CRPC (pending) B. Eigl/K. Chi

11:15 CUOG TRIALS: OPEN

CUOG-R-05 Role of Delayed Treatment for Early Stage RCCa M. Jewett

CHICS **Open Label, Phase II Trial of MAB Dose Escalation of Bicalutamide For Biochemical Failure In Prostate Cancer Patients** L. Klotz

CUOG TE-05 Sutent as salvage therapy in NSGCT C. Kollmannsberger

IAS plus dutasteride in PSA failures L. Klotz/S. Larry Goldenberg

ELAAT Early vs. Late Androgen Ablation Therapy A. Loblaw

SMART Phase II Study of SU011248 for maintenance therapy in HRPC after 1st line chemotherapy B. Eigl

Second-line bladder study (single arm Abraxane) Y. Ko

SPRUCE Randomized, placebo-controlled Phase II Study of SU011248 plus Best Supportive Care (BSC) versus Placebo plus BSC in patients with advanced urothelial carcinoma who have failed cisplatin containing chemotherapy T. Cheng

3066K1-404-WW Temsirolimus second line RCC trial in sutent failure F. Saad/L. Wood

VENICE Docetaxel +/- VEGF TRAP (R1R2) for First line HRPC I. Tannock

ZD4054 Trials:

ENTHUSE M0 **A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-Metastatic Hormone Resistant Prostate Cancer**

ENTHUSE M1C **A Phase III Trial of ZD4054 (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer**

12:15 LUNCH

1:20 CUOG TRIALS: CLOSED

CUOG P-03c Taxotere as Second Line in HRPC F. Saad

CUOG P-03a Iressa for Rising PSA post RP L. Klotz

CUOG B-05 BMS/CUOG second line bladder trial with vinflunine E. Winquist

CUOG-P-04-1 RCT Risedronate vs. Placebo for the Prevention of Androgen Deprivation Bone Loss in Non-Metastatic Prostate Cancer F. Saad

CUOG P-06b Phase II Study of Patupilone (Epo906a) As A 2nd Line Therapy in HRPC K. Chi

CUOG P-06c Phase II Study of OGX-011 + mitoxantrone vs. OGX-011 + docetaxel as A 2nd Line Chemotherapy in HRPC F. Saad/E. Winquist

ENTHUSE M1 - A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

CUOG TRIALS: PENDING

None

2:00 NEW TRIAL PROPOSALS/DOG REPORTS

3:00 OPEN DISCUSSION: NEW BUSINESS, STRATEGIC PLANNING

3:30 EXECUTIVE (CLOSED)